<DOC>
	<DOCNO>NCT00004084</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate cancer cell deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody therapy treat patient lymphoma leukemia respond previous chemotherapy .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Lymphoma Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity yttrium Y 90-labeled humanize anti-CD22 monoclonal antibody LL2 ( 90Y-hLL2 IgG ) patient B-cell malignancy . II . Determine pharmacokinetics biodistribution indium In 111 humanized LL2 ( 111In-hLL2 IgG ) patient . III . Evaluate immunogenicity repeat injection 90Y-hLL2 IgG patient . IV . Determine whether 90Y-hLL2 IgG versus indium In 131 humanized LL2 IgG therapeutic advantage base organ tumor dosimetry obtain 111In-hLL2 IgG . OUTLINE : This dose escalation study . Patients stratify risk group ( high vs low ) . Patients receive pretherapy image indium In 111 humanized LL2 IgG IV 30 minute day -7 0 . Patients receive yttrium Y 90-labeled humanize anti-CD22 monoclonal antibody LL2 ( 90Y-hLL2-IgG ) IV 30 minute day 0 . Cohorts 3-6 patient receive escalate dos 90Y-hLL2-IgG maximum tolerate dose ( MTD ) determine . The MTD define dose precede dose 2 3 2 6 patient experience dose limit toxicity . Patients follow every 2 week 1 month , monthly 2 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 18-24 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm Bcell malignancy , include Bcell nonHodgkin 's lymphoma Bcell chronic lymphocytic leukemia , fail least one regimen standard chemotherapy At least 1 confirmed tumor site radiolabeled LL2 IgG No great 25 % bone bone marrow involvement No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL AST alkaline phosphatase less 1.5 time upper limit normal ( ULN ) ( except bone involvement ) Renal : Creatinine le 1.5 time ULN Other : Not pregnant Fertile patient must use effective contraception 36 month study HIV negative No severe anorexia , nausea , vomit No significant concurrent medical condition would interfere compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Prior murine monoclonal antibody therapy allow ( unreactive yttrium Y 90labeled humanize antiCD22 monoclonal antibody LL2 HPLC ELISA test ) Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : At least 2 week since prior corticosteroid ( except adrenal insufficiency ) Radiotherapy : At least 4 week since prior radiotherapy index lesion No prior extensive radiotherapy great 25 % bone marrow ( except total body irradiation part bone marrow stem cell transplantation regimen engraftment functional marrow ( i.e. , produce normal peripheral blood count ) No prior maximum tolerate dose level radiotherapy critical organ ( e.g. , lung , liver , kidney ) Surgery : At least 4 week since prior major surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>